Results 101 to 110 of about 24,471 (215)
Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands [PDF]
, 2012 Background The first meningococcal serogroup C (MenC) conjugate vaccine was licensed in 1999 and introduced in the United Kingdom. Countries that have implemented the MenC vaccine since then in their national immunisation programmes use different ...
Patricia Kaaijk +4 more
core +2 more sources
The Update, February 13, 2012 [PDF]
, 2012 The Update is a bi-weekly web newsletter published by the Iowa Department of Public Health's Bureau of Family Health. It is posted the second and fourth week of every month, and provides useful job resource information for departmental health care ...
core
Human Papillomavirus Vaccine Frequency for University of Kansas Medical Center Pediatric Patients [PDF]
, 2019 Background. Human papillomavirus (HPV) vaccination is recommendedfor all adolescents aged 11 to 12 years, but coveragein Kansas is exceptionally poor. To understand local coverage, receiptof the 3-dose HPV vaccine series among pediatric patients atthe ...
Demo, Andrew +5 more
core +2 more sources
Infection and Drug Resistance, 2014 Carine P Hedari,* Rima W Khinkarly,* Ghassan S Dbaibo Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon ...
Hedari CP, Khinkarly RW, Dbaibo GS
doaj
Immunization Update, April 2008, Vol. 1, no. 7 [PDF]
, 2008 Monthly newsletter for the Iowa Department of Public ...
core
Биопрепараты: Профилактика, диагностика, лечение, 2018 Despite the progress in fighting against infectious diseases of bacterial origin, the incidence of generalized forms of meningococcal infection (GFMI) remains a topical public health problem not only in countries with historical high incidence, but also ...
M. V. Abramtseva +2 more
doaj
Expert Review of VaccinesIntroduction Individuals with immunocompromising conditions (e.g. asplenia, complement deficiency, HIV infection) or with high exposure to Neisseria meningitidis (e.g.
Shravani Bobde +3 more
doaj +1 more source
Strategic evaluations and techno-economic networks. Vaccine innovation in the Cuban biotech sector: for public health – or for profits? [PDF]
In this paper the Cuban biotech sector with its highly integrated vaccine industry is analyzed in the perspective of the techno-economic network model of Michel Callon. The paper discusses the strategic evaluations that have been performed in the sector.
Jens Plahte
core
Meningococcal conjugate vaccines: optimizing global impact
Infection and Drug Resistance, 2011 Andrew Terranella1,2, Amanda Cohn2, Thomas Clark2 1Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office, 2Meningitis and Vaccine Preventable Diseases Branch, National Center for ...
Terranella A, Cohn A, Clark T
doaj
Impact of meningococcal group B OMV vaccines, beyond their brief
Human Vaccines & Immunotherapeutics, 2018 Meningococcal group B outer membrane vesicle vaccines have been used widely in Cuba, New Zealand, and Brazil. They are immunogenic and initially assessed largely by their ability to induce serum bactericidal activity.
Helen Petousis-Harris
doaj +1 more source